Importantly, TMEM219 agonists may represent a novel therapy for tumors with significantly lower expression of IGFBP-3 but not TMEM219 compared to the counterpart normal tissues, such as breast invasive carcinoma, uterine corpus endometrial carcinoma, liver hepatocellular carcinoma, and prostate adenocarcinoma. Here, IGFBP3 is linked to uterine corpus endometrial carcinoma.